1. subject with a history of sars-cov-2 vaccinations within 1 months before randomization. 2. subject with a history of sars-cov-2 infection within 6 months before randomization. 3. with any serious infection requiring systemic anti-infective therapy within 14 days before randomization. 4. allergic to the investigational agent or any components of the formulation. pregnant or breast-feeding women. 5. women of childbearing potential who are unwilling to practice highly effective contraception during the study, and for at least 6 months after the study; sexually active men who are unwilling to use medically acceptable birth control during the study period. 6. have other conditions not suitable for inclusion as judged by the investigator.

1. subject with a history of sars-cov-2 vaccinations within 1 months before randomization. 2. subject with a history of sars-cov-2 infection within 6 months before randomization. 3. with any serious infection requiring systemic anti-infective therapy within 14 days before randomization. 4. allergic to the investigational agent or any components of the formulation. pregnant or breast-feeding women. 5. women of childbearing potential who are unwilling to practice highly effective contraception during the study, and for at least 6 months after the study; sexually active men who are unwilling to use medically acceptable birth control during the study period. 6. have other conditions not suitable for inclusion as judged by the investigator.

subject with a history of sars-cov-2 vaccinations within 1 months before randomization. subject with a history of sars-cov-2 infection within 6 months before randomization. with any serious infection requiring systemic anti-infective therapy within 14 days before randomization. allergic to the investigational agent or any components of the formulation. pregnant or breast-feeding women. women of childbearing potential who are unwilling to practice highly effective contraception during the study, and for at least 6 months after the study; sexually active men who are unwilling to use medically acceptable birth control during the study period. have other conditions not suitable for inclusion as judged by the investigator.

subject with a history of sars-cov-2 vaccinations within 1 months before randomization. subject with a history of sars-cov-2 infection within 6 months before randomization. with any serious infection requiring systemic anti-infective therapy within 14 days before randomization. allergic to the investigational agent or any components of the formulation. pregnant or breast-feeding women. women of childbearing potential who are unwilling to practice highly effective contraception during the study, and for at least 6 months after the study; sexually active men who are unwilling to use medically acceptable birth control during the study period. have other conditions not suitable for inclusion as judged by the investigator.